Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Shares Outstanding (Weighted Average) (2016 - 2025)

BioCorRx's Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $17.0 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Weighted Average) rose 86.76% year-over-year to $17.0 million; the TTM value through Jun 2025 reached $17.0 million, up 86.76%, while the annual FY2024 figure was $10.5 million, 25.41% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2025 was $17.0 million at BioCorRx, up from $15.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $17.0 million in Q2 2025 and bottomed at $6.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $7.9 million (2023), against an average of $8.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 6.18% in 2022 before it soared 86.76% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $6.5 million in 2021, then grew by 10.9% to $7.2 million in 2022, then rose by 15.92% to $8.3 million in 2023, then rose by 25.41% to $10.5 million in 2024, then surged by 62.57% to $17.0 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Shares Outstanding (Weighted Average) are $17.0 million (Q2 2025), $15.1 million (Q1 2025), and $10.5 million (Q4 2024).